<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4590">
  <stage>Registered</stage>
  <submitdate>8/08/2014</submitdate>
  <approvaldate>8/08/2014</approvaldate>
  <nctid>NCT02221505</nctid>
  <trial_identification>
    <studytitle>Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia</studytitle>
    <scientifictitle>A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CLOP628X2101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cKIT-positive Solid Tumors</healthcondition>
    <healthcondition>AML</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LOP628

Experimental: LOP628 - Solid Tumor - with LOP628

Experimental: LOP628 - AML - With LOP628

Experimental: LOP628 - Solid Tumor Expansion - With LOP628


Treatment: drugs: LOP628


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incident rate of dose limiting toxicities (DLTs) - To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)</outcome>
      <timepoint>Month 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs) and serious adverse events (SAE) - Characterize the safety and tolerability of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of adverse events (AEs) and serious adverse events (SAEs) - Characterize the safety and tolerability of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum PK parameters (AUC, Cmax, Tmax, and half-life) - To characterize the pharmacokinetic profile of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration vs. time profiles - To characterize the pharmacokinetic profile of LOP628.</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR) - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control Rate (DCR) at 4 months - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best overall response (BOR) - To assess the preliminary anti-tumor activity of LOP628 in patients</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best Overall Response (AML) - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) (AML) - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event Free Survival (EFS) (AML) - To assess the preliminary anti-tumor activity of LOP628</outcome>
      <timepoint>30 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For patients with solid tumors:

          -  documented cKit-positive neoplasms

          -  Patient must have progressive disease as defined by any of the following:

          -  SCLC: patient has progressed after at least 1 prior therapy

          -  GIST : patient has relapsed or has refractory disease, and no further approved
             effective therapeutic option exists

          -  Patients with other cKit-positive solid tumors: patient has progressed after at least
             one prior line of therapy and no further approved effective therapeutic option exists

          -  Patient has measurable disease as per RECIST v1.1 criteria

        For patients with AML:

          -  documented cKit-positive acute myelogenous leukemia

          -  Consent to newly obtained bone marrow aspirate

          -  Patient must have progressive disease defined as relapsed or refractory non-PML AML
             following standard therapy or for whom no effective therapy exists.

          -  Blast count &lt; 50,000/mm3</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>For patients with solid tumors:

          -  Patient has central nervous system (CNS) metastatic involvement unless the CNS
             metastases have been previously treated and the patient is clinically stable and on a
             stable dose of corticosteroids for at least 4 weeks prior to enrollment.

          -  Patient has the presence of other clinically significant hematologic, cardiac,
             respiratory, gastrointestinal, renal, hepatic or neurological conditions.

          -  Patient has a history of serious allergic reactions, which in the opinion of the
             investigator may pose an increased risk of serious infusion reactions

          -  Patient has been previously treated with cKit directed antibodies

          -  Pregnant or nursing women

        For patients with AML:

          -  Patient has received prior allogeneic bone marrow transplant (BMT).

          -  Patient has the presence of other clinically significant cardiac, respiratory,
             gastrointestinal, renal, hepatic or neurological disease

          -  Patient has a history of serious allergic reactions, which in the opinion of the
             investigator may pose an increased risk of serious infusion reactions

          -  Patient has been previously treated with cKit directed antibodies

          -  Pregnant or nursing women</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>LOP628 is an antibody-drug conjugate (ADC) consisting of an anti-cKit humanized IgG1/?
      antibody conjugated to a maytansine payload via a non-cleavable linker.

      LOP628 provides an opportunity to target cKit overexpressing tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02221505</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>